Incremental Health Care Costs of Self-Reported Functional Impairments and Phenotypic Frailty in Community-Dwelling Older Adults : A Prospective Cohort Study
- PMID: 37011386
- PMCID: PMC10121958
- DOI: 10.7326/M22-2626
Incremental Health Care Costs of Self-Reported Functional Impairments and Phenotypic Frailty in Community-Dwelling Older Adults : A Prospective Cohort Study
Abstract
Background: Health care systems need better strategies to identify older adults at risk for costly care to select target populations for interventions to reduce health care burden.
Objective: To determine whether self-reported functional impairments and phenotypic frailty are associated with incremental health care costs after accounting for claims-based predictors.
Design: Prospective cohort study.
Setting: Index examinations (2002 to 2011) of 4 prospective cohort studies linked with Medicare claims.
Participants: 8165 community-dwelling fee-for-service beneficiaries (4318 women, 3847 men).
Measurements: Weighted (Centers for Medicare & Medicaid Services Hierarchical Condition Category index) and unweighted (count of conditions) multimorbidity and frailty indicators derived from claims. Self-reported functional impairments (difficulty performing 4 activities of daily living) and frailty phenotype (operationalized using 5 components) derived from cohort data. Health care costs ascertained for 36 months after index examinations.
Results: Average annualized costs (2020 U.S. dollars) were $13 906 among women and $14 598 among men. After accounting for claims-based indicators, average incremental costs of functional impairments versus no impairment in women (men) were $3328 ($2354) for 1 impairment increasing to $7330 ($11 760) for 4 impairments; average incremental costs of phenotypic frailty versus robust in women (men) were $8532 ($6172). Mean predicted costs adjusted for claims-based indicators in women (men) varied by both functional impairments and the frailty phenotype ranging from $8124 ($11 831) among robust persons without impairments to $18 792 ($24 713) among frail persons with 4 impairments. Compared with the model with claims-derived indicators alone, this model resulted in more accurate cost prediction for persons with multiple impairments or phenotypic frailty.
Limitation: Cost data limited to participants enrolled in the Medicare fee-for-service program.
Conclusion: Self-reported functional impairments and phenotypic frailty are associated with higher subsequent health care expenditures in community-dwelling beneficiaries after accounting for several claims-based indicators of costs.
Primary funding source: National Institutes of Health.
Figures
Comment in
-
Function and Frailty: Value Added in Medicare.Ann Intern Med. 2023 Apr;176(4):578-579. doi: 10.7326/M23-0563. Epub 2023 Apr 4. Ann Intern Med. 2023. PMID: 37011393 No abstract available.
References
-
- Lassman D, Hartman M, Washington B, Andrews K, Catlin A. US health spending trends by age and gender: selected years 2002–10. Health Aff (Millwood). 2014. May;33(5):815–22. - PubMed
-
- Congressional Budget Office. High-Cost Medicare Beneficiaries [Internet]. 2005. [cited 2022 Aug 30]. Available from: www.cbo.gov/publication/16487
-
- Long P, Abrams M, Milstein A, Anderson G, Lewis Apton K, Lund Dahlberg M, et al. Effective Care for High-Need Patients: Opportunities for Improving Outcomes, Value, and Health [Internet]. Washington, D.C.: National Academy of Medicine; 2017. [cited 2022 Nov 15]. 213 p. Available from: https://nam.edu/wp-content/uploads/2017/06/Effective-Care-for-High-Need-... - PubMed
-
- Berkman ND, Chang E, Seibert J, Ali R. Characteristics of High-Need, High-Cost Patients : A “Best-Fit” Framework Synthesis. Ann Intern Med. 2022. Nov 8; - PubMed
-
- Centers for Medicare & Medicaid Services. Risk Adjustment [Internet]. 2022. [cited 2022 Jun 10]. Available from: https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Ris...
Publication types
MeSH terms
Grants and funding
- U01 AG032947/AG/NIA NIH HHS/United States
- R01 AG067973/AG/NIA NIH HHS/United States
- R01 AR035584/AR/NIAMS NIH HHS/United States
- U01 AG042145/AG/NIA NIH HHS/United States
- R01 AG005407/AG/NIA NIH HHS/United States
- U01 AG042168/AG/NIA NIH HHS/United States
- U01 AG042140/AG/NIA NIH HHS/United States
- R01 AG028050/AG/NIA NIH HHS/United States
- R01 AR035582/AR/NIAMS NIH HHS/United States
- U01 AG042143/AG/NIA NIH HHS/United States
- U01 AR066160/AR/NIAMS NIH HHS/United States
- R01 AR035583/AR/NIAMS NIH HHS/United States
- UL1 TR000128/TR/NCATS NIH HHS/United States
- R56 AG057498/AG/NIA NIH HHS/United States
- R01 AG066671/AG/NIA NIH HHS/United States
- U01 AG042124/AG/NIA NIH HHS/United States
- R01 AG027576/AG/NIA NIH HHS/United States
- R01 NR012459/NR/NINR NIH HHS/United States
- U01 AG027810/AG/NIA NIH HHS/United States
- R01 AG005394/AG/NIA NIH HHS/United States
- U01 AG042139/AG/NIA NIH HHS/United States
- R01 AG027574/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources